Bovipain-2, the falcipain-2 ortholog, is expressed in intraerythrocytic stages of the tick-transmitted hemoparasite Babesia bovis
© Mesplet et al; licensee BioMed Central Ltd. 2010
Received: 13 September 2010
Accepted: 23 November 2010
Published: 23 November 2010
Cysteine proteases have been shown to be highly relevant for Apicomplexan parasites. In the case of Babesia bovis, a tick-transmitted hemoparasite of cattle, inhibitors of these enzymes were shown to hamper intraerythrocytic replication of the parasite, underscoring their importance for survival.
Four papain-like cysteine proteases were found to be encoded by the B. bovis genome using the MEROPS database. One of them, the ortholog of Plasmodium falciparum falcipain-2, here named bovipain-2, was further characterized. Bovipain-2 is encoded in B. bovis chromosome 4 by an ORF of 1.3 kb, has a predicted molecular weight of 42 kDa, and is hydrophilic with the exception of a transmembrane region. It has orthologs in several other apicomplexans, and its predicted amino acid sequence shows a high degree of conservation among several B. bovis isolates from North and South America. Synteny studies demonstrated that the bovipain-2 gene has expanded in the genomes of two related piroplasmids, Theileria parva and T. annulata, into families of 6 and 7 clustered genes respectively. The bovipain-2 g ene is transcribed in in vitro cultured intra-erythrocyte forms of a virulent and an attenuated B. bovis strain from Argentina, and has no introns, as shown by RT-PCR followed by sequencing. Antibodies against a recombinant form of bovipain-2 recognized two parasite protein bands of 34 and 26 kDa, which coincide with the predicted sizes of the pro-peptidase and mature peptidase, respectively. Immunofluorescence studies showed an intracellular localization of bovipain-2 in the middle-rear region of in vitro cultured merozoites, as well as diffused in the cytoplasm of infected erythrocytes. Anti-bovipain-2 antibodies also reacted with B. bigemina-infected erythrocytes giving a similar pattern, which suggests cross-reactivity among these species. Antibodies in sera of two out of six B. bovis-experimentally infected bovines tested, reacted specifically with recombinant bovipain-2 in immunoblots, thus demonstrating expression and immunogenicity during bovine-infecting stages.
Overall, we present the characterization of bovipain-2 and demonstrate its in vitro and in vivo expression in virulent and attenuated strains. Given the involvement of apicomplexan cysteine proteases in essential parasite functions, bovipain-2 constitutes a new vaccine candidate and potential drug target for bovine babesiosis.
The tick-transmitted apicomplexan hemoprotozoon Babesia bovis continues to impose serious limitations to cattle development worldwide [1, 2]. A better understanding of its pathogenic mechanisms and the exploitation of the recently sequenced genome  is needed for the identification of molecules that are involved in the host-pathogen and vector-pathogen interface, which can lead to improved control strategies against this parasite.
The search for relevant parasite molecules can benefit from the information available for Plasmodium falciparum, another arthropod vector-transmitted apicomplexan protozoon with an intraerythrocytic life stage, that shares pathogenicity mechanisms with B. bovis. Plasmodial peptidases have been shown to play vital functional roles and have been proposed as vaccine candidates . The best characterized P. falciparum peptidases are the falcipains, which are cysteine peptidases that belong to clan CA, subfamily C1A.
Assortment of peptidases into clans is based on the presence of sequence motifs around the catalytic residues, their evolutionary relationships and/or similarities in their tertiary structure. Clans, in turn, are subdivided in families, according to their amino acid sequence similarities. Cysteine peptidases of clan CA utilize catalytic glutamine, cysteine, histidine and asparagine residues that are invariably in this order . These four amino acids are present in three separate, well conserved regions of the primary sequence that correspond to the mature protease, which are known as the eukaryotic thiol (cysteine) proteases cysteine, histidine, and asparagine active site regions.
Falcipain-2 has shown to be involved in digestion of host erythrocyte hemoglobin in the parasite food vacuole [7, 8]. The amino acids that result from this process are used for parasite protein synthesis [9, 10], and contribute to maintain the osmotic stability of the parasite . Hemoglobin degradation might provide space for the growth of the parasite inside the erythrocyte . Additionally, falcipain-2 has been shown to cleave host erythrocyte membrane skeletal proteins ankyrin and protein 4.1. The removal of the carboxyl terminus of ankyrin weakens its interaction with the erythrocyte membrane and yields an increased rate of membrane fragmentation of infected erythrocytes . In addition, falcipain-2 cleaves protein 4.1 within a region of the spectrin-actin binding domain critical for erythrocyte membrane stability . It has been postulated that the proteinase-induced ankyrin and protein 4.1 degradation destabilizes the erythrocyte membrane skeleton, which in turn facilitates parasite release . Furthermore, it has been shown that cysteine peptidases might be involved in the differentiation of plasmodial gametocytes into ookinetes. Torres et al  demonstrated that serine/cysteine protease inhibitors TPCK and TLCK, but not the serine protease specific inhibitors PMSF and leupeptin, inhibited exflagellation centers formation, suggesting a participation of cysteine proteases in P. berghei gamete activation and zygote development.
Cysteine proteinases have been shown to play critical roles in the pathogenicity of other parasitic protozoans as well. Thus, they have been identified as virulence factors in Leishmania amazonensis and Entamoeba histolytica[17, 18]. Virulence is intimately associated with proteolysis and invasion of cells and/or tissues by intracellular and extracellular parasites . Accordingly, cysteine proteinases of Toxoplasma gondii and Trypansoma cruzi have been found to be involved in host cell and tissue invasion and egress [18, 20]. Adherence of E. histolytica to erythrocytes and epithelial cells as well as excystation processes of Cryptosporidium sp. and Giardia sp.  have been shown to be mediated by parasite cysteine proteinases.
This type of enzyme is ubiquitous in all kingdoms of organisms. In mammals, cysteine proteinases function in diverse processes like apoptosis, prohormone processing, tissue remodelling, turnover of the extracellular matrix, and extracellular degradation of foreign proteins [21, 22]. Importantly, lysosomal cysteine peptidases also regulate the immune response by mediating antigen presentation of classical MHC class II and non-classical MHC class-I molecule CD1D .
Cysteine peptidases have so far not been characterized in B. bovis. However, evidence of their importance for the survival of these parasites was obtained by the observation that specific inhibitors of these enzymes impaired merozoite growth in vitro. As in P. falciparum, cysteine peptidases may be involved in the erythrocyte egress of B. bovis merozoites, a prerequisite for the maintenance of the asexual propagation of the parasite, and/or nutrition of the trophozoite and merozoite parasite stages that reside within the erythrocyte through degradation of hemoglobin. Additionally, B. bovis cysteine peptidases may also play an important role in several differentiation steps of the parasite (sporozoite, trophozoite, merozoite, kinete) as well as in invasion and evasion processes within the tick vector tissues.
The aim of this work has been to identify and characterize the falcipain-2 ortholog in B. bovis, as well as to make an inventory of cysteine proteinases in this parasite and two related piroplasmids.
Identification of putative cysteine peptidases of the C1 family in the B. bovis T2Bo genome
Babesia bovis cysteine peptidase C1 family
Predicted protein length (aa)
Catalytic region localization
MEROPS annotation of catalytic region
cysteine protease 2
papain homolog (Theileria type) (C01.079)
papain family cysteine peptidase
papain homolog (Theileria type) (C01.079)
cathepsin C precursor
dipeptidylpeptidase I (Plasmodium type) (CO1.124)
cathepsin C precursor
dipeptidylpeptidase I (Plasmodium type) (CO1.124)
Molecular characterization of bovipain-2
Babesia bovis bovipain-2-related proteins in other apicomplexan organisms
cysteine peptidase 2
cysteine peptidase precursor, tacP
Post-translational modification of 3 sites that are potentially N-glycosylated (N113, N198, and N221) and 1 site that is potentially O-glycosylated (T204) could be predicted based on sequons in the propeptide/spacer region of bovipain-2. As the available bioinformatic tools have been developed for mammalian organisms, the validity of these predictions in Babesia needs to be verified by direct experimental evidence.
The mature enzyme owns three stretches of amino acids that contain the catalytic residues (Q254, C260, H389, and N411). Upon folding, these amino acid sequences configure the 3D structure of the catalytic center of the proteinase. These three stretches are known as 1) eukaryotic thiol (cysteine) proteases cysteine (aa 254 to 265), 2) histidine (aa 387 to 397), and 3) asparagine (aa 406 to 425) active site regions, since these residues are essential for enzymatic activity. Their sequence is highly conserved among several apicomplexan parasites, as shown in Figure 2.
Strain polymorphism of bovipain-2
Position of polymorphic amino acid residue
Common physico-chemical characteristics
Synteny and phylogenetic studies with Theileria annulata and T. parva cysteine peptidases
Transcription and expression of bovipain-2 in B. bovis in vitro cultured merozoites
Antigenicity of bovipain-2 in B. bovis-infected cattle
Partially purified recombinant bovipain-2 was tested in immunoblots against serum samples from bovines experimentally infected with the BboS2P (n = 3) or the BboR1A (n = 3) strains of B. bovis (day 63 p.i.). Non B. bovis-reactive sera from two bovines from a tick-free region of Argentina were used as negative controls. Only one of the BboS2P-infected and one of the BboR1A-infected sera reacted with recombinant bovipain-2 (Figure 5B), while all BboS2P and BboR1A sera strongly reacted with recombinant MSA-2c (not shown), a previously characterized immunodominant protein of B. bovis. These results indicate that bovipain-2 is expressed and immunogenic in the course of bovine infections with these two strains.
P. falciparum falcipain-2 has received a great amount of attention as a target for therapeutic interventions against malaria, due to its relevant functional role . This work identifies and characterizes bovipain-2, the B. bovis ortholog of falcipain-2. The biological significance of this protein is underscored by the observation that B. bovis growth can be inhibited using cysteine-proteinase inhibitors .
Based on their sequences, falcipain-2 and bovipain-2 are classifiable as cysteine peptidases belonging to Clan CA, subfamily C1A. This peptidase subfamily is characterized by the presence of four catalytic Q, C, H, and A residues present in three separate, well conserved regions of the primary sequence that corresponds to the mature protease, which are known as the eukaryotic thiol (cysteine) proteases cysteine, histidine, and asparagine active site regions (Figure 2). In the final tertiary conformation of the protein, the catalytic amino acids are brought together and constitute the enzyme active site. Importantly, predicted models of the putative catalytic site in falcipain-2 and bovipain-2 showed a similar arrangement of the relevant C, H, and N regions that form the active site of the enzyme in both proteins, despite high sequence polymorphisms in the intervening regions (data not shown). Furthermore, alignment of bovipain-2 orthologs from different apicomplexan parasites showed strict conservation of the catalytic residues and low polymorphism in their surrounding areas (Figure 2). Additionally, full sequence conservation was observed among bovipain-2 protein sequences of B. bovis geographical isolates in the whole region that harbors the active site. This constraint for genetic variation is likely due to the need for keeping the structural conformation of the protein in order to preserve its activity. Thus, taken together these data support a cysteine protease function for bovipain-2, similar to what was previously described for falcipain-2.
Interestingly, apart from bovipain-2, only 3 other C1 cysteine proteinase encoding genes seem to be present in the B. bovis-genome. The bovipain-2 encoding gene corresponds to gene families in T. annulata and T. parva of 7 and 6 members, respectively. In contrast, the other cysteine proteinase encoding genes of B. bovis have a single ortholog equivalent in T. parva and T. annulata. We hypothesize that the expanded cysteine-protease family of bovipain-2 type may have a specific function in T. parva and T. annulata associated with the additional schizont parasite stage and more complex life cycle of Theileria sp. parasites. However, this notion would need to be demonstrated in future investigations. Gene duplications and tandem arrays of similar isoforms of clan CA peptidases have also been found in other related protozoan parasites, but the biological implications of this phenomenon remain unclear .
In P. falciparum falcipain-2 localizes in the food vacuole, where hemoglobin digestion takes place . However, falcipain-2 expression was detected also outside of the food vacuole and near the erythrocyte membrane skeleton which is consistent with the proposed involvement of erythrocyte membrane skeletal protein cleavages in merozoite egress . The punctate immunofluorescence pattern shown in Figure 6 indicates that, similar to its P. falciparum ortholog, bovipain-2 also appears to be localized in a yet undefined, internal organelle of the parasite. Food vacuoles have been described in Babesia sp. but only on the basis of morphological evidence [32, 33]. Thus, further investigations need to be carried out to more exactly elucidate the intracellular location of bovipain-2. However, similarly to Plasmodium, anti-bovipain-2 antibodies also reacted with the cytoplasm of B. bovis-infected erythrocytes of different strains tested, while smears of non-infected erythrocytes showed no reactivity. These observations suggest first, that bovipain-2 and erythrocyte proteases do not share cross-reactive B-cell epitopes and also, that bovipain-2 is released into the erythrocyte cytoplasm. Occasionally, some erythrocytes in which no parasites could be detected showed cytoplasmic reactivity in smears of B. bovis-infected erythrocytes (data not shown). Since non-infected erythrocyte smears showed no reactivity with anti-bovipain-2 antibodies, a possible explanation for this observation is that the parasites egressed from the reactive erythrocytes before the smears were prepared, leaving released proteins behind. Reactivity towards empty erythrocytes of antibodies that recognize babesial proteins was previously observed in the case of the merozoite spherical body protein, Bb-1, which can be found on the cytoplasmic side of the erythrocyte membrane . It has been suggested that Bb-1 is secreted by B. bovis into the erythrocyte cytoplasm, where it might be involved in invasion and/or exit processes.
Anti-bovipain-2 antibodies cross-reacted with B. bigemina merozoites. A 48.5% identity in the predicted amino acid sequences of bovipain-2 and a putative B. bigemina protein named babesipain [35, 36] (Table 2) could be responsible for the observed cross-reactivity. The cytoplasm of B. bigemina-infected erythrocytes also reacted with anti-bovipain-2 antibodies, suggesting that release of babesipain from B. bigemina merozoites has also taken place.
Expression of cysteine proteases in cultured, wild type or attenuated B. bovis parasites can be affected by distinct possible selective pressures. This is significant since the pattern and level of expression of cysteine proteases were also regarded as potential factors affecting the virulence of parasites . Sera from bovines experimentally infected either with the BboS2P or BboR1A Argentinean strains reacted with the recombinant bovipain-2, confirming in vivo expression and immunogenicity of the protein in the blood stages of the parasites regardless of their degree of virulence.
However, because four out of six sera from infected animals tested failed to recognize recombinant bovipain-2, the results also suggest that bovipain-2 might be poorly immunogenic during acute infection. It has been reported that subdominant antigens may prove to be more effective as vaccine candidates than immunodominant antigens . Based on this supposition, bovipain-2 constitutes an interesting candidate for subunit vaccine development. Alternatively, it is possible that these sera also contain antibodies reactive with conformational epitopes in the native protein that are not able to recognize the recombinant version of bovipain-2.
In silico analysis of the B. bovis predicted proteome using the MEROPS database has shown the presence of 66 proteases, that belong to the cysteine (n = 18), serine (n = 18), metallo (n = 19), threonine (n = 6) and aspartic (n = 5) classes (manuscript in preparation). Although this number is small compared to P. falciparum (n = 93), the high number of protease-encoding genes appears to indicate that these enzymes participate in critical metabolic processes and/or signalling mechanisms that need to be separately regulated. On-going experiments to analyze which of these proteases are transcribed in the merozoite and other stages of the parasite life cycle will throw light on their possible functional roles and their suitability as targets for improved control methods for bovine babesiosis.
Collectively, the data presented in this study identifies and demonstrates the in vitro and in vivo expression of bovipain-2, a cysteine protease, in Babesia bovis. Because this family of proteases plays significant roles in the biology of related parasites, they might become additional targets for improving the control of bovine babesiosis. Whether antibodies against bovipain-2 present during natural infection reduce the parasite burden and whether this protein is a viable candidate for vaccine development or for new anti-babesial drugs will be the subject of future research.
C1 cysteine peptidases were identified from the proteome as predicted by the genome of Babesia bovis (T2Bo strain), Theileria annulata (Ankara strain) and T. parva (Mumuga strain)  using the MEROPS database [6, 39]. Orthology was established when the complete genome sequence of the corresponding organism was available using reciprocal BLASTP best hit . Percentages of protein identity were calculated using a BLOSUM62 matrix. Possible deleterious effects of amino acid substitutions on protein function were predicted by SIFT [41, 42]; which takes into account sequence homology and the physical properties of amino acids. After alignment of the amino acid sequences of the catalytic region of cysteine proteinases of B. bovis, T. annulata and T. parva by clustalw , their phylogenetic relationship was constructed by neighbor joining using MEGA4 [44, 45]. Synteny studies were carried out with GEvo [46, 47]. Parameter settings using BLASTZ were as follows: word size 8, gap opening penalty 400, gap extension penalty 30, and score threshold 1800. The minimum high scoring sequence pair (HSP) length for overlapped features was set to 50. For the prediction of glycosylation, NetNGlyc and NetOGlyc were used [48–50].
Samples and DNA extraction
The following B. bovis strains and isolates were used: BboR1A, an Argentine vaccinial strain ; BboS2P and BboM3P, pathogenic isolates derived from clinical cases in Salta and Corrientes, Argentina, respectively; Veracruz, a pathogenic isolate from Mexico ; Brazil and Uruguay, which originated from clinical cases from these countries.
BboR1A and BboS2P strains were maintained in in vitro culture on bovine erythrocytes in M199 medium, supplemented with 40% bovine serum, at 37°C, basically as described by Levy and Ristic  but using a regular 10% CO2 atmosphere. BboM3P, Brazil, Uruguay and Veracruz isolates were amplified in splenectomized calves. In vitro cultured merozoites were partially purified by differential centrifugation as previously described . In the case of parasites amplified in splenectomized calves, whole blood was centrifuged (3000 × g, 30 min, 4°C), the pellet was frozen at -20°C overnight, and then washed thrice with PBS by centrifugation (3000 × g, 30 min, 4°C) to remove released hemoglobin. DNA was purified from both kinds of samples with phenol/chloroform/isoamylic alcohol (Sigma-Aldrich, St. Louis, MO) extraction and ethanol precipitation, using established procedures , followed by RNAse (USB, Cleveland, OH; 20 μg/ml, 45 min, 45°C) and proteinase K (USB; 100 μg/ml, overnight, 45°C) treatment. DNA samples were re-extracted, dissolved in distilled water, quantified by spectrophotometry, and kept at -20°C until use.
An aliquot of DNA (50 ng) was added to a PCR mix (25 μl final volume) containing 2 mM Cl2Mg, 200 μM each dNTP, 1 U Taq polymerase (Invitrogen) and 0.4 μM bovipain-F and bovipain-R primers (5'-ATGGAAATACCGGCTGCTG-3' and 5'-ATATGGGACATAACCGTAAG-3', respectively). After 10 min incubation at 95°C, samples were subjected to 35 cycles of: 60 s at 95°C, 45 s at 55°C and 60 s at 72°C, followed by an extension period of 10 min at 72°C. Amplicons were visualized in ethidium bromide-stained 0.8% agarose gels and sized by comparison with a 1 kb Plus DNA ladder (Invitrogen).
Total RNA was extracted from 5 × 106 infected erythrocytes of in vitro cultured B. bovis BboS2P and BboR1A parasites, using the NucleoSpin RNAII kit (Macherey-Nagel, Germany), according to the manufacturer's instructions. RNA integrity was protected with 1 U/ul of Riboblock (Fermentas, Burlington, Canada). Samples were then treated with DNAse (Invitrogen) for 15 min at room temperature, followed by addition of 2 mM EDTA and incubation at 65°C for 10 min for DNAse inactivation. The final samples were kept at -80°C until use.
RNA aliquots (150 ng) from either the BboS2P or the BboR1A strain of B. bovis were incubated with SuperScript III One-Step RT-PCR with Platinum Taq DNA Polymerase (Invitrogen), 2× reaction mix (following the manufacturer's protocol), and 0.4 μM of bovipain-F and bovipain-R primers in a final reaction volumen of 25 μl. Parallel negative controls were prepared, containing the same composition without Reverse Transcriptase. As positive control, primers that amplify the MSA-2c transcript  were used with the same RNA samples. All samples were incubated for 30 min at 55°C, followed by 2 min at 94°C and then subjected to 40 cycles of 45 s at 94°C, 45 s at 55°C and 60 s at 68°C, with a final extension period of 5 min at 68°C. Amplicons were visualized and sized as described above.
PCR and RT-PCR amplicons were purified using the GFX PCR DNA and Gel Band Purification kit (GE Healthcare), and both strands were sequenced using specific primers, at the Internal Service of Genotyping and Sequencing Ibiotec (Institute of Biotechnology, CICVyA, INTA-Castelar, Argentina). The Big Dye Terminator v3.1 kit (Applied Biosystems, Carlsbad, CA, USA) and a 3130xl Genetic Analyzer equipment (Applied Biosystems) were employed.
Expression and purification of recombinant bovipain-2
The entire bovipain-2 ORF, amplified by PCR from DNA of B. bovis BboR1A was cloned into pCR2.1 vector (Invitrogen). The correct reading frame of the recombinant construct was verified by sequencing. After digestion of bovipain-2-pCR2.1 with EcoR I (Promega, Madison, WI), the restriction fragment was purified using GFX PCR DNA and Gel Band Purification kit (GE Healthcare) and cloned in-frame in the prokaryotic expression vector pRSETB (Invitrogen). E. coli Rosetta (DE3, Novagen) cells were transformed with the recombinant vector and expression was induced by overnight exposure to 1 mM IPTG (Invitrogen) in Luria Broth medium containing 50 μg/ml ampicillin and 35 μg/ml chloramphenicol (Sigma-Aldrich). Cells were pelleted by centrifugation and the pellet was solubilized in Laemmli buffer. Aliquots of this lysate were electrophoresed in preparative 12% polyacrylamide minigels in the presence of SDS. A protein molecular weight marker (Fermentas) was run in parallel to size the bands. Gel sections containing 50-55 kDa proteins were excised, and placed in a cellulose membrane dialysis tubing retaining proteins of molecular weight of 12 kDa or greater (Sigma-Aldrich). Proteins were electroeluted in a horizontal electrophoresis chamber at 35 mA for 2.5 h in SDS-PAGE running buffer, followed by dialysis against PBS.
For Western blots, samples were 5× concentrated inside the dialysis membranes by exposure to solid sucrose at room temperature, followed by dialysis against PBS. Finally, 1 mM PMSF, final concentration (Calbiochem, San Diego, CA) was added, protein concentration was measured by the Micro BCA Protein Assay Kit (Pierce, Rockford, USA), and samples were stored at -80°C until use.
Production of antisera
Adult male Balb-c mice (n = 2) were inoculated with bovipain-2, produced and partially purified by electroelution as described above, emulsified in Sigma Adjuvant System (Sigma-Aldrich). Inoculations took place at days 0, 20, 40 and 55 and each consisted in 200 μl emulsion, containing 50 μg of protein, which were administered in several spots through the subcutaneous and intraperitoneal routes. Hyperimmune serum aliquots were collected by heart puncture at day 70 p.i. after euthanizing the mice with CO2.
Detection of bovipain-2 expression in in vitro cultured merozoites
In vitro-cultured B. bovis BboS2P merozoites were purified by centrifugation in Percoll gradients as described before . Samples containing 7 μg of protein were dissolved in Laemmli buffer, electrophoresed in 10% polyacrylamide minigels in the presence of SDS, and transferred to nitrocellulose membranes. A protein molecular weight standard from Fermentas was run in the same gels. Blots were blocked with 10% (w/v) dry low-fat milk in PBS/0.01% Tween-20 (PBST) and incubated with a pool of mouse anti-bovipain-2 hyperimmune serum (day 70 p.i.), or with a pool of serum obtained at day 0 from the same mice (1/50 dilution in blocking buffer). After three washes with PBST, reactivity of antibodies with merozoite proteins was detected by incubation with peroxidase-labeled anti-mouse IgG (Santa Cruz Biotechnologies, CA) followed by ECL reagent (GE Healthcare). Chemiluminiscence was visualized on Hyperfilm sheets (GE Healthcare) developed with Kodak photographic reagents (Rochester, NY).
Reactivity against bovipain-2 of sera from B. bovis-infected cattle
Partially purified recombinant bovipain-2 obtained as described above was electrophoresed in 12% polyacrylamide gels in the presence of SDS, followed by transfer to nitrocellulose membranes, blocking as above, and incubation with the following sera: a) monoclonal anti-histidine antibody (GE Healthcare); b) bovine sera negative to B. bovis antibodies from a tick-free region of Argentina (n = 2); or c) sera of bovines experimentally infected with B. bovis BboR1A (n = 3) or BboS2P (n = 3), (day 63 p.i.). Sera from groups (b) and (c) were pre-incubated with an E. coli lysate (0.1 mg/ml, 37°C, 1 h). Bovine sera were tested in 1/10 dilution. Blot (a) was incubated with peroxidase-labeled anti-mouse IgG, and blots (b) and (c) with peroxidase-labeled anti-bovine IgG (Santa Cruz Biotechnologies) and the reactions were visualized by ECL chemiluminiscence. As positive control, recombinant B. bovis MSA-2c  was used.
Indirect immunofluorescence assay
Aliquots (5 ml) of in vitro cultured suspensions of B. bovis merozoites in bovine erythrocytes (10-15% infected erythrocytes) from the strains BboS2P (Argentina) or RAD (Mexico); or with in vitro cultures of B. bigemina, strains BbiS2P or Mexico, were washed thrice with PBS by centrifugation and resuspended in PBS/0.5% normal horse serum. Smears of these suspensions or of non infected erythrocytes (5 μl) were prepared, divided in sections with Enamel paint and incubated with: a) normal mouse serum in a 1/60 dilution; b) a pool of two anti-bovipain-2 mouse sera (70 dpi) in the same dilution; and c) anti-RAP-1 23/70.174 Mab , 8 μg/ml. The fixed immunofluorescence assay was carried out as described before , using fluorescein isothiocyanate (FITC)-labeled goat anti-mouse IgG (Dacko, Glostrup, Denmark), or donkey anti-mouse Alexa Fluor 488 (Molecular Probes, Invitrogen, Eugene, OK). Slides were mounted with glycerol/PBS (1:1, v/v) and observed under fluorescence microscopy (400 and 1000 × magnification).
List of abbreviations
N-α-p-tosyl-L-lysine chloromethyl ketone
The experimental work was supported by grants from ANPCyT (PICT 2002-00054) and INTA (AERG 232152), Argentina; the European Commission (INCO 003691 MEDLABAB, and INCO 245145 PIROVAC), and the Wellcome Trust (075800/Z/04/Z), UK. Salaries were provided by CONICET (MM, Ph.D. Fellow; and MFC and LS, Researchers); INTA (IE, MD), USDA (CES) and the Univeristy of Queretaro (JJM). The authors deeply thank Dr. João Ricardo Martins (IPVDF, Porto Alegre, Brasil) and Dra. María Solari (DILAVE"Miguel C. Rubino", Montevideo, Uruguay) for kindly providing Brazil and Uruguay B. bovis strain, respectively; Dr. Marisa Farber, Institute of Biotechnology (IB), CICVyA, INTA; and Med. Vet. Daniel Benitez, EEA-Mercedes, INTA, for the maintenance and provision of the Uruguay and Brazil isolates, and the BboM3P isolate, respectively. The assistance of Guillermo Maroniche, IB, CICVyA, INTA, for the observation of IFA slides and of Erick Lyons, UC Berkely, for his assistance in the Genome Evolution Analysis, are gratefully acknowledged.
- Bock R, Jackson L, de Vos A, Jorgensen W: Babesiosis of cattle. Parasitology. 2004, 129 (Supp l): S247-269. 10.1017/S0031182004005190.View ArticlePubMed
- Florin-Christensen M, Schnittger L, Dominguez M, Mesplet M, Rodriguez A, Ferreri L, Asenzo G, Wilkowsky S, Farber M, Echaide I, Suarez C: Search for Babesia bovis vaccine candidates. Parassitologia. 2007, 49 (Suppl 1): 9-12.PubMed
- Brayton KA, Lau AO, Herndon DR, Hannick L, Kappmeyer LS, Berens SJ, Bidwell SL, Brown WC, Crabtree J, Fadrosh D, Feldblum T, Forberger HA, Haas BJ, Howell JM, Khouri H, Koo H, Mann DJ, Norimine J, Paulsen IT, Radune D, Ren Q, Smith RK, Suarez CE, White O, Wortman JR, Knowles DP, McElwain TF, Nene VM: Genome sequence of Babesia bovis and comparative analysis of apicomplexan hemoprotozoa. PLoS Pathog. 2007, 3: 1401-13. 10.1371/journal.ppat.0030148.View ArticlePubMed
- Krause PJ, Daily J, Telford SR, Vannier E, Lantos P, Spielman A: Shared features in the pathobiology of babesiosis and malaria. Trends Parasitol. 2007, 23: 605-610. 10.1016/j.pt.2007.09.005.View ArticlePubMed
- Sajid M, McKerrow JH: Cysteine proteases of parasitic organisms. Mol Biochem Parasitol. 2002, 120: 1-21. 10.1016/S0166-6851(01)00438-8.View ArticlePubMed
- Rawlings ND, Barrett AJ, Bateman A: MEROPS: the peptidase database. Nucleic Acids Res. 2010, 38: D227-233. 10.1093/nar/gkp971.PubMed CentralView ArticlePubMed
- Shenai BR, Sijwali PS, Singh A, Rosenthal PJ: Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum. J Biol Chem. 2000, 275: 29000-29010. 10.1074/jbc.M004459200.View ArticlePubMed
- Sijwali PS, Brinen LS, Rosenthal PJ: Systematic optimization of expression and refolding of the Plasmodium falciparum cysteine protease falcipain-2. Protein Expr Purif. 2001, 22: 128-134. 10.1006/prep.2001.1416.View ArticlePubMed
- Moulder JW: Comparative biology of intracellular parasitism. Microbiol Rev. 1985, 49: 298-337.PubMed CentralPubMed
- McKerrow JH, Sun E, Rosenthal PJ, Bouvier J: The proteases and pathogenicity of parasitic protozoa. Annu Rev Microbiol. 1993, 47: 821-853. 10.1146/annurev.mi.47.100193.004133.View ArticlePubMed
- Lew VL, Tiffert T, Ginsburg H: Excess hemoglobin digestion and the osmotic stability of Plasmodium falciparum-infected red blood cells. Blood. 2003, 101: 4189-4194. 10.1182/blood-2002-08-2654.View ArticlePubMed
- Rosenthal PJ: Cysteine proteases of malaria parasites. Int J Parasitol. 2004, 34: 1489-1499. 10.1016/j.ijpara.2004.10.003.View ArticlePubMed
- Dua M, Raphael P, Sijwali PS, Rosenthal PJ, Hanspal M: Recombinant falcipain-2 cleaves erythrocyte membrane ankyrin and protein 4.1. Mol Biochem Parasitol. 2001, 116: 95-99. 10.1016/S0166-6851(01)00306-1.View ArticlePubMed
- Hanspal M, Dua M, Takakuwa Y, Chishti AH, Mizuno A: Plasmodium falciparum cysteine protease falcipain-2 cleaves erythrocyte membrane skeletal proteins at late stages of parasite development. Blood. 2002, 100: 1048-1054. 10.1182/blood-2002-01-0101.View ArticlePubMed
- Dhawan S, Dua M, Chishti AH, Hanspal M: Ankyrin peptide blocks falcipain-2-mediated malaria parasite release from red blood cells. J Biol Chem. 2003, 278: 30180-30186. 10.1074/jbc.M305132200.View ArticlePubMed
- Torres JA, Rodriguez MH, Rodriguez MC, de la Cruz Hernandez-Hernandez F: Plasmodium berghei: effect of protease inhibitors during gametogenesis and early zygote development. Exp Parasitol. 2005, 111: 255-259. 10.1016/j.exppara.2005.08.003.View ArticlePubMed
- de Araujo Soares RM, dos Santos AL, Bonaldo MC, de Andrade AF, Alviano CS, Angluster J, Goldenberg S: Leishmania (Leishmania) amazonensis: differential expression of proteinases and cell-surface polypeptides in avirulent and virulent promastigotes. Exp Parasitol. 2003, 104: 104-112. 10.1016/S0014-4894(03)00135-8.View ArticlePubMed
- Klemba M, Goldberg DE: Biological roles of proteases in parasitic protozoa. Annu Rev Biochem. 2002, 71: 275-305. 10.1146/annurev.biochem.71.090501.145453.View ArticlePubMed
- Carruthers VB: Proteolysis and Toxoplasma invasion. Int J Parasitol. 2006, 36: 595-600. 10.1016/j.ijpara.2006.02.008.View ArticlePubMed
- Teo CF, Zhou XW, Bogyo M, Carruthers VB: Cysteine protease inhibitors block Toxoplasma gondii microneme secretion and cell invasion. Antimicrob Agents Chemother. 2007, 51: 679-688. 10.1128/AAC.01059-06.PubMed CentralView ArticlePubMed
- Chapman HA, Riese RJ, Shi GP: Emerging roles for cysteine proteases in human biology. Annu Rev Physiol. 1997, 59: 63-88. 10.1146/annurev.physiol.59.1.63.View ArticlePubMed
- Dickinson DP: Cysteine peptidases of mammals: their biological roles and potential effects in the oral cavity and other tissues in health and disease. Crit Rev Oral Biol Med. 2002, 13: 238-275. 10.1177/154411130201300304.View ArticlePubMed
- Honey K, Rudensky AY: Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol. 2003, 3: 472-482. 10.1038/nri1110.View ArticlePubMed
- Okubo K, Yokoyama N, Govind Y, Alhassan A, Igarashi I: Babesia bovis: effects of cysteine protease inhibitors on in vitro growth. Exp Parasitol. 2007, 117: 214-217. 10.1016/j.exppara.2007.04.009.View ArticlePubMed
- Mehlhorn H, Schein E: Redescription of Babesia equi Laveran, 1901 as Theileria equi Mehlhorn, Schein 1998. Parasitol Res. 1998, 84: 467-475. 10.1007/s004360050431.View ArticlePubMed
- Pain A, Bohme U, Berry AE, Mungall K, Finn RD, Jackson AP, Mourier T, Mistry J, Pasini EM, Aslett MA: The genome of the simian and human malaria parasite Plasmodium knowlesi. Nature. 2008, 455: 799-803. 10.1038/nature07306.PubMed CentralView ArticlePubMed
- Reduker DW, Jasmer DP, Goff WL, Perryman LE, Davis WC, McGuire TC: A recombinant surface protein of Babesia bovis elicits bovine antibodies that react with live merozoites. Mol Biochem Parasitol. 1989, 35: 239-247. 10.1016/0166-6851(89)90210-7.View ArticlePubMed
- Wilkowsky SE, Farber M, Echaide I, Torioni de Echaide S, Zamorano PI, Dominguez M, Suarez CE, Florin-Christensen M: Babesia bovis merozoite surface protein-2c (MSA-2c) contains highly immunogenic, conserved B-cell epitopes that elicit neutralization-sensitive antibodies in cattle. Mol Biochem Parasitol. 2003, 127: 133-141. 10.1016/S0166-6851(02)00329-8.View ArticlePubMed
- Ettari R, Bova F, Zappala M, Grasso S, Micale N: Falcipain-2 inhibitors. Med Res Rev. 2010, 30: 136-167.PubMed
- Atkinson HJ, Babbitt PC, Sajid M: The global cysteine peptidase landscape in parasites. Trends Parasitol. 2009, 25: 573-581. 10.1016/j.pt.2009.09.006.PubMed CentralView ArticlePubMed
- Subramanian S, Sijwali PS, Rosenthal PJ: Falcipain cysteine proteases require bipartite motifs for trafficking to the Plasmodium falciparum food vacuole. J Biol Chem. 2007, 282: 24961-24969. 10.1074/jbc.M703316200.View ArticlePubMed
- Rudzinska MA, Trager W: Intracellular phagotrophy in Babesia rodhaini as revealed by electron microscopy. J Protozool. 1962, 9: 279-288.View ArticlePubMed
- Slomianny C, Charet P, Prensier G: Ultrastructural localization of enzymes involved in the feeding process in Plasmodium chabaudi and Babesia hylomysci. J Protozool. 1983, 30: 376-382.View ArticlePubMed
- Hines SA, Palmer GH, Brown WC, McElwain TF, Suarez CE, Vidotto O, Rice-Ficht AC: Genetic and antigenic characterization of Babesia bovis merozoite spherical body protein Bb-1. Mol Biochem Parasitol. 1995, 69: 149-159. 10.1016/0166-6851(94)00200-7.View ArticlePubMed
- Martins TM, Goncalves LM, Capela R, Moreira R, do Rosario VE, Domingos A: Effect of synthesized inhibitors on babesipain-1, a new cysteine protease from the bovine piroplasm Babesia bigemina. Transbound Emerg Dis. 2010, 57: 68-69. 10.1111/j.1865-1682.2010.01102.x.View ArticlePubMed
- Martins TM, do Rosário VE, Domingos A: Identification of papain-like cysteine proteases from the bovine piroplasm Babesia bigemina and evolutionary relationship of piroplasms C1 family of cysteine proteases. Exp Parasitol.
- Brown WC, Norimine J, Knowles DP, Goff WL: Immune control of Babesia bovis infection. Vet Parasitol. 2006, 138: 75-87. 10.1016/j.vetpar.2006.01.041.View ArticlePubMed
- National Center for Biotechnology Information. [http://ncbi.nlm.nih.gov/]
- MEROPS database. [http://merops.sanger.ac.uk]
- Tatusov RL, Koonin EV, Lipman DJ: A genomic perspective on protein families. Science. 1997, 278: 631-637. 10.1126/science.278.5338.631.View ArticlePubMed
- Kumar P, Henikoff S, Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009, 4: 1073-1081. 10.1038/nprot.2009.86.View ArticlePubMed
- SIFT. [http://sift.jcvi.org/index.html]
- Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22: 4673-4680. 10.1093/nar/22.22.4673.PubMed CentralView ArticlePubMed
- Saitou N: The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987, 4: 406-425.PubMed
- Kumar S, Dudley J, Tamura K: MEGA: a biologist-centric software for evolutionary analysis of DNA and protein sequences. Brief Bioinform. 2008, 9: 299-306. 10.1093/bib/bbn017.PubMed CentralView ArticlePubMed
- Lyons E, Freeling M: How to usefully compare homologous plant genes and chromosomes as DNA sequences. Plant J. 2008, 53: 661-673. 10.1111/j.1365-313X.2007.03326.x.View ArticlePubMed
- GEvo. [http://synteny.cnr.berkeley.edu/CoGe/GEvo.pl]
- Julenius K, Molgaard A, Gupta R, Brunak S: Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites. Glycobiology. 2005, 15: 153-164. 10.1093/glycob/cwh151.View ArticlePubMed
- NetNGlyc 1.0 Server. [http://www.cbs.dtu.dk/services/NetNGlyc]
- NetOGlyc 3.1 Server. [http://www.cbs.dtu.dk/services/NetOGlyc]
- Anziani OS, Guglielmone AA, Abdala AA, Aguirre DH, Mangold AJ: Protección conferida por Babesia bovis vacunal en novillos Holando Argentino. Rev Med Vet (Buenos Aires). 1993, 74: 47-49.
- Nevils MA, Figueroa JV, Turk JR, Canto GJ, Le V, Ellersieck MR, Carson CA: Cloned lines of Babesia bovis differ in their ability to induce cerebral babesiosis in cattle. Parasitol Res. 2000, 86: 437-443. 10.1007/s004360050691.View ArticlePubMed
- Levy MG, Ristic M: Babesia bovis: continuous cultivation in a microaerophilous stationary phase culture. Science. 1980, 207: 1218-1220. 10.1126/science.7355284.View ArticlePubMed
- Rodriguez SD, Buening GM, Vega CA, Carson CA: Babesia bovis: purification and concentration of merozoites and infected bovine erythrocytes. Exp Parasitol. 1986, 61: 236-243. 10.1016/0014-4894(86)90157-8.View ArticlePubMed
- Ausubel FM: Short Protocols in Molecular Biology. 2002, New York, NY John Wiley & Sons, Inc
- de Rios LC, Aguirre DH, Gaido AB: Evaluación de la dinámica de la infección por Babesia bovis y Babesia bigemina en terneros. Diagnóstico por microscopía directa y prueba de inmunofluorescencia indirecta. Rev Med Vet. 1988, 69: 254-260.
- Pain A, Renauld H, Berriman M, Murphy L, Yeats CA, Weir W, Kerhornou A, Aslett M, Bishop R, Bouchier C: Genome of the host-cell transforming parasite Theileria annulata compared with T. parva. Science. 2005, 309: 131-133. 10.1126/science.1110418.View ArticlePubMed
- Gardner MJ, Bishop R, Shah T, de Villiers EP, Carlton JM, Hall N, Ren Q, Paulsen IT, Pain A, Berriman M: Genome sequence of Theileria parva, a bovine pathogen that transforms lymphocytes. Science. 2005, 309: 134-137. 10.1126/science.1110439.View ArticlePubMed
- Holman PJ, Hsieh MM, Nix JL, Bendele KG, Wagner GG, Ball JM: A cathepsin L-like cysteine protease is conserved among Babesia equi isolates. Molecular and Biochemical Parasitology. 2002, 119: 295-300. 10.1016/S0166-6851(01)00423-6.View ArticlePubMed
- Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S: Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 2002, 419: 498-511. 10.1038/nature01097.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.